Merck KGaA, Darmstadt, Germany acquires SpringWorks Therapeutics, Inc. (2025)

Deal facts

Buyer: Merck KGaA, Darmstadt, Germany
Target: SpringWorks Therapeutics, Inc.
Deal value: Not disclosed
Announced: 27 April 2025
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

1 Jul 2025CompletedClosed
Merck KGaA, Darmstadt, Germany completes acquisition of SpringWorks Therapeutics, Inc.
INTRODUCTORY NOTE On July 1, 2025 (the “ Closing Date ”), Merck KGaA, Darmstadt, Germany, a German corporation with general partners (“ Parent ”), completed the previously announced acquisition of SpringWorks Therapeutics, Inc., a Delaware corporation (the “ Company ” or “ SpringWorks ”), pursuant to the Agreement and Plan of Merger, dated April 27, 2025 (the “ Merger Agreement ”), by and among Sp
Source

OpinionExit Mode editorial

We see a clear strategic signal in the completed acquisition of SpringWorks Therapeutics by Merck KGaA. This transaction represents a cross-border move where a German life sciences giant secures a US-based biotech asset through an all-cash deal. The fact that the consideration is purely cash speaks volumes about the buyer's confidence and the seller's desire for certainty. For the SME founder in the biotech sector, this structure removes the volatility of share-based payments and delivers immediate liquidity. It suggests that strategic buyers are willing to pay a premium for proven platforms that fit their long-term pipeline, provided the science aligns with their core therapeutic areas.

The regulatory context here is significant. A deal of this nature, spanning the US and the EU, would have triggered a rigorous review by both the US Federal Trade Commission and the European Commission to ensure no competition issues arise. The completion status confirms that all necessary antitrust thresholds were met and any change-of-control covenants were satisfied without delay. This smooth clearance is a positive indicator for the sector, showing that regulators are not blocking strategic consolidation in healthcare when the assets are complementary. It also highlights the importance of having clean governance and transparent clinical data before entering negotiations, as any hidden compliance gaps could have derailed the timeline.

Our view is that this deal underscores the value of being a specialist in a niche therapeutic area. SpringWorks was not a generalist player but a focused entity with a specific portfolio that Merck needed. The all-cash nature of the deal implies that the buyer saw immediate value and did not need to rely on earn-out contingencies to bridge valuation gaps. This is a crucial distinction for founders who often face pressure to accept deferred payments. The market is rewarding clear strategic fit with upfront capital, reducing the risk of post-close disputes over performance targets.

Founders should review their current pipeline against the strategic gaps of the top five global players in their sector this week. Identify which specific therapeutic areas these giants are underweight in and prepare a one-page summary of how your asset fills that gap. Do not wait for a broker to make the introduction; reach out directly to the business development teams at those firms with this specific alignment in mind.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More strategic acquisition deals More from Merck KGaA, Darmstadt, Germany All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

7 May 2026CompletedHealthcare

Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.

Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.

Buyer: Shuttle Pharmaceuticals Holdings, Inc.
Target: United Dogecoin Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

29 April 2026CompletedHealthcare

MedPal AI plc to acquire Remedi Solutions Limited

MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.

Buyer: MedPal AI plc
Target: Remedi Solutions Limited
Deal value: GBP 310,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

27 April 2026CompletedHealthcare

BIOMARIN PHARMACEUTICAL INC to acquire Amicus

BIOMARIN PHARMACEUTICAL INC and Amicus entered the Exit Mode archive.

Buyer: BIOMARIN PHARMACEUTICAL INC
Target: Amicus
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

22 April 2026CompletedHealthcare

Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Telomir Pharmaceuticals, Inc.
Target: TELI Pharmaceuticals, Inc.
Deal value: USD 34,389,710
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

15 April 2026CompletedHealthcare

GSK plc to acquire 35Pharma Inc.

GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…

Buyer: GSK plc
Target: 35Pharma Inc.
Deal value: USD 950,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Canada deals

Buyer history